Physiological glucose-sensing pathways

Physiological glucose-sensing pathways refer to the complex network of molecular sensors and signaling cascades that allow an organism to monitor and respond to changes in blood glucose concentrations. These pathways are primarily localized in specialized cells within the pancreas, brain, and gut, where they coordinate the release of metabolic hormones such as insulin and glucagon to maintain homeostasis (Alexander et al., 2021). Key molecular components involved in these processes include the sweet taste receptor heterodimer (TAS1R2 and TAS1R3) and various intracellular metabolic enzymes that couple glucose metabolism to cellular excitability. Despite their fundamental role in metabolic regulation, many of these pathways are currently classified as non-validated drug targets because they lack clinically approved pharmacological modulators (IUPHAR/BGP, 2023). Dysregulation of glucose sensing is a critical factor in the development of metabolic diseases, most notably type 2 diabetes and obesity, where the body's ability to sense or respond to glucose is impaired. While some individual proteins within these pathways are targets for existing therapies, the broader sensing mechanisms themselves remain a challenge for drug development due to the risk of systemic side effects like hypoglycemia. Research continues to focus on these pathways to identify novel therapeutic windows for treating metabolic syndrome.

Other names

Glucose sensing mechanismsMetabolic glucose sensorsGlucose-sensing pathways

No validated pharmacological modulators are currently approved for these specific sensing pathways.